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Abstract: The carotid body (CB) is an important organ located at the carotid bifurcation that
constantly monitors the blood supplying the brain. During hypoxia, the CB immediately triggers
an alarm in the form of nerve impulses sent to the brain. This activates protective reflexes including
hyperventilation, tachycardia and vasoconstriction, to ensure blood and oxygen delivery to the brain
and vital organs. However, in certain conditions, including obstructive sleep apnea, heart failure
and essential/spontaneous hypertension, the CB becomes hyperactive, promoting neurogenic
hypertension and arrhythmia. G-protein-coupled receptors (GPCRs) are very highly expressed
in the CB and have key roles in mediating baseline CB activity and hypoxic sensitivity. Here, we
provide a brief overview of the numerous GPCRs that are expressed in the CB, their mechanism
of action and downstream effects. Furthermore, we will address how these GPCRs and signaling
pathways may contribute to CB hyperactivity and cardiovascular and respiratory disease. GPCRs
are a major target for drug discovery development. This information highlights specific GPCRs that
could be targeted by novel or existing drugs to enable more personalized treatment of CB-mediated
cardiovascular and respiratory disease.
Keywords: G-protein; GPCR; carotid body; hypoxia; hypertension; drug-discovery
1. Introduction
The carotid body (CB) is a vital sensory organ, located near the carotid bifurcation, that constantly
monitors blood supplying the brain [1]. The CB is stimulated by acute hypoxia, upon which it rapidly
activates vital cardiovascular and respiratory reflexes, including peripheral vasoconstriction, elevated
heart rate and increased breathing [2]. These ensure that sufficient blood-oxygen is delivered to
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the brain to support survival. It is now apparent that there are numerous G-protein-coupled receptors
(GPCRs) expressed in the CB, and that modulation of these receptors is able to alter baseline CB
activity and the sensitivity to hypoxia. Indeed, components of GPCR signaling pathways represent
some of the most highly expressed genes in the rodent CB [3]. Three different types of GPCR alpha
subunit have been identified to date in the CB: Gαs, Gαi and Gαq, and each one of these subtypes has
a unique mechanism of action. Activation of Gαs will lead to transmembrane adenylyl cyclase (tmAC)
stimulation, which in turn leads to an increase in intracellular cyclic adenosine monophosphate (cAMP).
In contrast, the activation of Gαi will lead to the inhibition of tmAC activity, which in turn decreases
cAMP [4,5]. The activation of Gαq stimulates phospholipase C (PLC), leading to the production of
diacylglycerol (DAG) and inositol trisphosphate (IP3), which can modify [Ca2+]i, protein kinase activity,
ion channel function and potentially also reactive oxygen species (ROS) generation [1]. Importantly,
the CB has gained attention clinically due to its hyperactivity in a number of conditions, including
obstructive sleep apnea (OSA), heart failure (HF) and essential/spontaneous hypertension (SH), in
which it promotes neurogenic hypertension and arrhythmia. Multiple GPCRs have been implicated in
CB hyperactivity, and these may offer key targets for novel drug discovery or repurposing. However,
as yet, there are no drugs used clinically that directly target the CB, and this will be required in order
to provide better and more personalized treatment of CB-mediated cardiovascular and respiratory
disease. The aim of this review is to briefly explore the role of the major GPCRs and associated ligands
in the CB, both in mediating normal CB function, hypoxic sensitivity and CB hyperactivity.
2. Gαs and Gαi Protein-Coupled Receptor Signaling in the Carotid Body
2.1. Adenosine and CD73
Adenosine is a precursor and a breakdown product of an important excitatory neurotransmitter
in the CB, ATP, which is tonically released from the type I cell [6]. Extracellular concentrations of
adenosine and ATP are reported to be approximately 20 pmol/CB and 4 pmol/CB respectively, in
normoxia and increase by 174% and 147% in mild hypoxia in the rat CB [7,8]. A2A and A2B-receptor
mRNA has been isolated from rat CBs, and immunocytochemical and in situ hybridization techniques
have shown that A2A- and A2B-receptors are present on the type I cell and A2A-receptors are expressed
on post-synaptic sensory fibers [9–12]. In contrast, A1- and A3-receptors do not appear to be present in
the CB [9,12].
CB activation by exogenous adenosine in vivo evokes an acute increase in respiratory frequency,
tidal volume and minute ventilation in the rat [13]. More recent studies have now also confirmed
that acute adenosine administration elevates ventilation in humans [14]. Exogenous adenosine
is capable of activating all aspects of the CB chemotransduction cascade, including inhibition of
Twik-related acid-sensitive K+ (TASK) and voltage-gated K+ channels, elevation of [Ca2+]i, promotion
of neurotransmitter release and stimulation of chemoafferent fibers [11,15–17].
Endogenous adenosine plays an important role in establishing baseline neurotransmitter
release and chemoafferent activity in normoxia [11,18]. The non-selective A2-receptor antagonist
8-(p-Sulfophenyl)theophylline (8-SPT) causes more than 90% depletion in chemoafferent frequency
when measured in the ex vivo CB preparation [18]. This is particularly important given that it is the rise
in baseline chemoafferent activity that most likely promotes chronic reflex stimulation and neurogenic
hypertension associated with OSA, SH and HF. Initial reports suggest that caffeine (an adenosine
receptor antagonist), does not modify the basal chemoafferent frequency in animals following exposure
to chronic intermittent hypoxia (CIH), a robust model of OSA [19]. However, it must be noted that
these animals displayed a reduction rather than elevation in baseline nerve activity, which is not
characteristic of other studies using CIH. More experiments are definitely warranted to evaluate this
further as well as a potential role for adenosine in mediating CB hyperactivity in SH and HF.
Adenosine also has an important role in mediating CB responses to hypoxia [20–22]
and hypercapnia [18,23]. Inhibition of adenosine receptors has a greater impact at low-intensity levels
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of hypoxia [8], suggesting that adenosine is important in establishing CB hypoxic sensitivity and/or
that adenosine release predominates under milder hypoxic conditions. However, the exact signaling
mechanism remains controversial. Both A2A- and A2B-receptors are coupled by the Gαs protein,
thus a role for adenylyl cyclase (AC) activation and cAMP accumulation appear highly likely [5,24].
In the whole CB preparation, A2B-, but not A2A-receptor antagonists depress catecholamine secretion
in hypoxia [11,25]. In these same studies, it was reported that both A2A- and A2B-receptor antagonists
reduce chemoafferent frequency in hypoxia, leading the authors to conclude that adenosine acts on
pre-synaptic A2B- and post synaptic A2A-receptors. This is supported by the finding that A2B- not
A2A-receptor inhibition suppresses type I cell catecholamine secretion and rises in [Ca2+]i induced by
adenosine in co-cultures with petrosal neurons [10]. However, in an earlier study, it was observed
that A2A-receptor antagonism almost completely abolished the adenosine-mediated elevation in Ca2+,
an effect that was mimicked by the protein kinase A (PKA) inhibitor H89 [17]. Other studies have
shown that H89 and other PKA inhibitors do not significantly alter the catecholamine release caused by
hypoxia [26]. This has led to the hypothesis that whilst increased adenosine and cAMP are important,
they may be acting independently of PKA. Alternative messengers of cAMP include exchange proteins
activated by cAMP (EPACs), which when activated, can overcome the inhibition of AC in the CB [26].
EPAC is suggested to be a key regulator of exocytotic machinery and K+ channels. Although no
direct link between adenosine and EPAC has yet been established, as studies so far have only looked
at the link between hypoxia and EPAC, a link is plausible and could be the focus of future investigations.
Another target could be the hyperpolarization-activated cation current Ih reported to be activated via
an A2A-receptor and cAMP-dependent mechanism on the post-synaptic site [27].
An important consideration is the actual source of adenosine in normoxia and hypoxia. It has
been suggested that adenosine may be formed inside type I cells by the breakdown of cAMP and ATP
and subsequently released through the bidirectional equilibrative nucleoside transporter (ENT) into
the synapse [7,8]. This source of adenosine might be expected to increase proportionally during
hypoxia as oxidative phosphorylation decreases and cAMP increases. It is therefore somewhat
surprising that the functional impact of adenosine is more apparent at low- rather than high-intensity
hypoxia [8]. Furthermore, our own experiments found that pharmacological inhibition of the ENT did
not modify chemoafferent frequency in either normoxia or hypoxia [22]. This is possibly suggestive of
an alternative source of adenosine.
It is now apparent that adenosine can be generated from extracellular ATP (Figure 1). In the CB,
a significant synaptic ATP concentration is due to the tonic vesicular neurosecretion from the type I
cell [28] and also through ATP release from type II cells via pannexin-1 channels [29]. There may also
be ATP release from red blood cells, although this remains to be clarified in the CB circulation.
CD73 (ecto-5′-nucleotidase) catalyzes the formation of adenosine from AMP, following initial
breakdown of ATP and adenosine diphosphate (ADP) by CD39 (ecto-nucleosidetriphosphate
diphosphohydrolase) [30]. RNA and protein expression of CD73 have now been identified in the CB
with the majority being localized to the type I cell [31]. Inhibiting CD73 with α,β-Methylene-ADP
(AOPCP) decreases the total pool of extracellular adenosine in the CB [7]. Furthermore, similar
pharmacological inhibition of CD73 causes a dramatic reduction in basal chemoafferent activity
and blunts the CB response to hypoxia in vitro and the cardiovascular-respiratory response to hypoxia
in vivo [22]. Given the high concentrations of AOPCP used in these studies, there is still a need to
validate these findings using genetic models or with lower doses of more selective CD73 inhibitors
that are becoming available. Consistent with a hypoxia-inducible factor-1 (HIF-1)-dependent elevation
of CD73 in other tissues, including hypoxic tumors [32], CB CD73 expression increases in response
to chronic hypoxia along with A2B-receptors [10,33]. Interestingly, a recent study shows that CD73
expression is elevated in the aged CB, despite an overall reduction in chemoreceptor function [34].
However, a role for CD73 in mediating CB hyperactivity in CIH, SH or HF remains to be elucidated.
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Figure 1. Schematic illustration of ecto-5′-nucleotidase (CD73)-mediated adenosine generation and 
signaling in the carotid body (CB). During normoxia/hypoxia, ATP released as a neurotransmitter can 
be converted to adenosine by the action of ecto-nucleosidetriphosphate diphosphohydrolase (CD39) 
and CD73. Alternatively, ATP can be converted to adenosine in the type I cell and released via the 
equilibrative nucleoside transporter (ENT). Adenosine binds to A2-receptors on the pre- and post-
synaptic membrane to increase baseline activity and overall hypoxic sensitivity. Filled lines denote 
purinergic signaling, dashed lines denote ion flow.  
2.2. Adrenaline 
Although adenosine is regarded as the major positive regulator of cAMP in the CB, there are 
other substances that may elevate cAMP. One of these is adrenaline. Adrenaline binds to β-
adrenoceptors, most commonly the β1 and β2 subtypes which are coupled to the Gαs subunit, resulting 
in cAMP elevation in heart and other tissue [35]. Although there is substantial evidence that 
adrenaline stimulates breathing [36,37], the direct effect on the CB is less clear. There are reports of 
exogenous adrenaline administration in vivo causing both increased and decreased CB 
chemoreceptor discharge [36,38,39]. The effect might be dependent on the dose/concentration used, 
whilst physiological concentrations selectively act on β-adrenoceptors, supra-physiological levels 
could act on D2-receptors leading to inhibition. This is supported in our own work where we 
identified a stimulatory effect at 10 nM but an inhibitory action at higher concentrations, as evidenced 
by a marked reduction in chemoafferent frequency [37,40]. 
What is more important to consider is the physiological relevance of endogenous adrenaline. 
Our own understanding of the effects of endogenous adrenaline have been developed through the 
study of the counter-regulatory response to hypoglycemia. During hypoglycemia, adrenaline levels 
rise [41], and hepatic glucose release increases to counter this fall. Multiple studies have now 
provided evidence of activation of the CB in response to hypoglycemia in animals [42,43] and humans 
[44,45]. This is essential not only to further augment hepatic glucose release but also to increase 
ventilation to match the concurrent rise in metabolic rate, initiated by adrenaline [43,46] (Figure 2). 
In these circumstances, a heightened CB CO2 sensitivity allows for increased chemoreceptor 
discharge and ventilation in the absence of any change in arterial blood gases. Recent evidence has 
shown that the increase in minute ventilation and CO2 sensitivity during hypoglycemia was blunted 
by propranolol treatment, removal of the adrenal gland and section of the carotid sinus nerve (CSN) 
[37]. This is consistent with the view that it is adrenaline that activates the CB during hypoglycemia, 
Figure 1. Schematic illustration of ecto-5′-nucleotidase (CD73)-mediated adenosine generation
and signaling in the carotid body (CB). During normoxia/hypoxia, ATP released as a neurotransmitter
can be converted to adenosine by the action of ecto-nucleosidetriphosphate diphosphohydrolase
(CD39) and CD73. Alternatively, ATP can be converted to adenosine in the type I cell and released
via the equilibrative nucleoside transporter (ENT). Adenosine binds to A2-receptors on the pre-
and post-synaptic membrane to increase baseline activity and overall hypoxic sensitivity. Filled lines
denote purinergic signaling, dashed lines denote ion flow.
2.2. Adrenaline
Although adenosine is regarded as the major positive regulator of cAMP in the CB, there are other
substances that may elevate cAMP. One of these is adrenaline. Adrenaline binds to β-adrenoc ptors,
most commo ly the β1 and β2 subtypes which are coupled to the Gαs subunit, resulting in cAMP
elevati n in heart and other tissue [35]. Although there is substantial evid nce that adrenaline stim lates
breathing [36,37], the direct effect on t e CB is less clear. There are reports of exogenous adrenaline
a mi istration in vivo causing both increase and decreased CB chemoreceptor discharg [36,38,39].
The effect might be dependent on the dose/concentration used, whilst physiological conc ntrations
sel ctively act on β-adrenoceptors, supra-physiological levels could ac on D2-receptors leading to
in ibi ion. This is support d in our own work where we identified a stimulatory effect at 10 nM but
an inhibitory action at higher concentrations, as evidenced by a marked reductio in chemoafferent
frequency [37,40].
What is more important to consid r is the physiological relevance of endogenous adrenaline. Our
own understanding of the effec s of endogenous adrenaline have be n developed through the study of
the counter-regulatory response to hyp glycemia. During hypoglycemia, adrenaline levels rise [41],
and hepatic glucose el ase inc eas t counter this fall. Multiple studies have now provided evid nce
of activatio of the CB in response to hypoglyc mia in a imals [42,43] and humans [44,45]. This is
essential not only to further augment hepatic gluco release but also to increase ventilatio to match
the concurrent rise in metabolic rate, initiated by adr aline [43,46] (Figure 2). In these circumstances,
a heightened CB CO2 s nsitivity allows for increased chemorec ptor discharge and ventilation in
the absence of any change in arterial blood gases. Recent evidence has shown that the inc ase in
m nute v ntilatio and CO2 sensitivity during hypoglycemia was blunted by propra olol tr atment,
removal of the adren l gland and section of the carotid sinu nerve (CSN) [37]. This is consistent with
the view that it is adrenalin that activates th CB during hypoglycemia, via β-adrenoceptors. Key
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experiments are now needed to see if this is also evident in humans. Perhaps surprisingly, no studies
have yet looked at a potential role for adrenaline in causing CB hyperactivity in OSA or HF, both of
which are associated with a chronic rise in plasma catecholamines. Chronic isoprenaline delivered via
osmotic mini-pump does elevate baseline breathing and responses to hypoxia and hypercapnia [40],
but as yet, the relevance of this model to pathology remains uncertain and studies in animals and/or
humans with HF and CIH are required [47]. Moreover, there is hardly any indication of how adrenaline
acts to augment CB chemosensitivity (even the specific receptor subtypes) and there is limited evidence
of the impact of beta-blockers on CB function. Key experiments are needed to establish if chronic
beta-blocker treatment (which are widely prescribed for heart failure, hypertension and arrhythmia)
dampens CB function such that there is increased vulnerability to hypoxic and hypoglycemic exposure.
As such, we are just beginning to grasp the importance of adrenaline in mediating CB function in
health and disease.
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activated by adrenaline. This activation will lead to an increase in CO2 sensitivity, neurotransmitter 
release and an increase in ventilation. The elevation in ventilation matches the increase in metabolic 
rate and CO2 generation (VCO2), such that the overall partial pressure of arterial CO2 (PaCO2) and pH 
remain constant. The ? denotes that the signaling mechanism linking increased CO2 sensitivity with 
enhanced neurotransmitter release is still unknown. Lines with arrows denote signaling pathways. 
Lines with circles and chevrons denote efferent neurons.  
2.3. Lactate and Olfr78 
Lactate signaling through the GPCR Olfr78 (Gαs) has gained significant attention based on the 
finding that Olfr78 mRNA is highly expressed in the murine CB and its global deletion completely 
abolishes the hypoxic ventilatory response (HVR) [48]. This was coupled with a complete depression 
of CB chemoafferent activity during hypoxia. Indeed, it is logical that both intracellular and systemic 
lactate levels increase during hypoxia after partial or complete termination of oxidative 
phosphorylation in the CB and other tissues, thereby providing a stimulus for Olfr78. The work has 
now been strengthened by evidence from another laboratory demonstrating a similar depression in 
the HVR in a different mouse strain [49]. However, this was in spite of severe hypoxia failing to 
depress the elevation in type I cell [Ca2+]i in Olfr78−/−, raising questions over the exact location of the 
Figure 2. Schematic illustration of adrenaline activation of the carotid body (CB) during hypoglycemia.
When blood glucose decreases, this is sensed in the brainstem and leads to a reflex increase in adrenaline
release from the adrenal medulla. β-adrenoceptors in type 1 cells will be activated by adrenaline.
This activation will lead to an increase in CO2 sensitivity, neurotransmitter release and an increase in
ventilation. The elevation in ventilation matches the increase in metabolic rate and CO2 generation
(VCO2), such that the overall partial pressure of arterial CO2 (PaCO2) and pH remain constant. The ?
denotes that the signaling mechanism linking increased CO2 sensitivity with enhanced neurotransmitter
release is still unknown. Lines with arrows denote signaling pathways. Lines with circles and chevrons
denote efferent neurons.
2.3. Lactate and Olfr78
Lactate signaling t PCR Olfr78 (Gαs) has gained s gnifican a te tion based on
the finding that Olfr78 mRNA is highly expressed in the murine CB and its global deletion completely
abolishes the hypoxic ventilatory response (HVR) [48]. This was coupled with a complet depression of
CB chemoafferent activity during hypoxia. Indeed, it is log cal that both intracellular and systemic lactate
levels incr ase during hypoxia after partial or com lete termination of oxidative phosphorylation in
the CB and other tissues, thereby provid ng a timulus for Olfr78. The work has now been strengthened
by evid nce from another laboratory de o strating a similar depre sion in the HVR in a differe t
mouse strai [49]. However, this was in spite of severe hypoxi failing to depr ss the elevation in type I
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cell [Ca2+]i in Olfr78−/−, raising questions over the exact location of the Olfr78 signaling within the CB
or chemoreflex pathway. Furthermore, this same study observed similar elevations in chemoafferent
nerve activity induced by lactate in Olfr78−/− and wildtype (WT) CBs, suggesting that another ligand,
and not lactate, activates Olfr78 during hypoxia. In contrast to these studies, it has also been reported
that that Olfr78−/− mice maintain a robust HVR and retain type I cell sensitivity to hypoxia [50]. Clearly
there is a need to reconcile these findings and in particular to study lactate and Olfr78 in higher species,
including humans, which have a larger chemoafferent response to hypoxia and are less susceptible
to respiratory alkalosis. In our own studies, we observed that after prolonged exposure to glucose
deprivation, which eventually caused chemoafferent excitation, 5 mM lactate acted to suppress rather
than excite chemoafferent frequency [51]. Despite being in a different experimental setting, we propose
that lactate may have an additional role as an alternative energy source, independent of Olfr78, similar
to that seen in the central nervous system (CNS) and peripheral nerves [52,53].
2.4. Dopamine and Noradrenaline
The CB contains a large amount of stored catecholamines (CAs) in dense core vesicles, and for
its mass, the overall CA content is equivalent only to that seen in adrenal medullary tissue [54].
The enzyme tyrosine hydroxylase (TH), that initiates the synthesis of CAs from tyrosine, has now
emerged as a well-established type I cell marker [55]. Dopamine (DA) is the most abundant CA in type I
cells, forming more than 50% of the overall CA content [54,56]. There is some evidence of dopamine
beta-hydroxylase expression in type I cells, consistent with small amounts of noradrenaline (NA) [57].
Interestingly, dopamine beta-hydroxylase is augmented in CBs of SH rats, possibly indicative of a more
pronounced role of NA as a transmitter in pathology [58]. Recently, it has been demonstrated that
type I cells contain significant amounts of vesicular monoamine transporter 1 (VMAT1), the enzyme
most likely responsible for incorporation of DA and NA into secretory vesicles [59,60]. This process
may also be highly sensitive to levels of biotin, a vitamin and coenzyme known to accumulate in
type I cells [59]. Future experiments may well evaluate how these enzymes are altered in CB-mediated
cardiovascular and metabolic disease.
DA is released from type I cells in abundance during hypoxia [61,62], but its action seems to be
autoinhibitory, providing the CB with a degree of inhibitory feedback control via D2-receptors [63–66].
Indeed, it has been suggested that the balance between dopamine (via Gαi-coupled D2-receptors)
and adenosine (via Gαs-coupled A2B-receptors) is critical in determining the overall cAMP level
and excitability within the type I cell [25]. The increase in [Ca2+]i in rat type I cells in response to
hypoxia can be attenuated by D2-receptor agonists [67]. D2-receptors have now also been positively
confirmed in the human CB [68] and DA infusion to depress CB function is commonly used to estimate
CB contribution to pathophysiological reflexes in humans [69–71]. Whether or not DA completely
silences the CB chemoafferent discharge in humans is unknown. Exogenous DA does indeed reduce
(but not abolish) the HVR in humans, but there is some considerable variability between individuals
and not all of the observed effects may be solely attributable to CB inhibition [72,73]. In mice with
global deficiency of D2-receptors, whilst type I cell neurotransmitter release was enhanced in response
to hypoxia, the chemoafferent activity was reduced and the HVR was unchanged [74]. In rats, the HVR
can be enhanced rather than depressed, by systemic inhibition of the monoamine oxidase enzyme,
which is likely to have increased free DA [75]. These studies are suggestive of additional locations
and possible excitatory functions of D2-receptors within the CB and/or chemoreflex pathway other
than the type I cell in rodents. Any excitatory action does not however seem to involve cAMP sensitive
hyperpolarization-activated currents (Ih), as evidenced by DA causing a reduction in this post-synaptic
current through a D2-receptor-mediated mechanism [27].
Reverse transcription polymerase chain reaction (RT-PCR) analysis of short- and long-term hypoxic
rats’ CBs showed a time-dependent increase in the expression of TH and D2-receptor genes [76,77]. After
48 hours of hypoxia, D2-receptor mRNA levels decreased, but after 7 days, the expression of D2-receptor
increased significantly [76]. The alteration in D2-receptor expression has been hypothesized to cause
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a change in DA signaling in the CB which contributes to the changes in ventilatory adaptation observed
with long-term hypoxia associated with chronic obstructive pulmonary disease (COPD) or HF [78].
A role for DA in establishing CB hyperactivity in response to CIH has recently been investigated [79].
In this study, CIH augmented CB DA content, CB catecholamine release and arterial blood pressure,
but not the HVR. Moreover, the D2-receptor antagonist domperidone reversed the elevation in blood
pressure and the excessive catecholamine release during hypoxia in CBs isolated from CIH animals.
This again goes against the idea that DA is simply an inhibitory neurotransmitter and opens up
the possibility that it has an excitatory function in the CB in certain pathological conditions. In this
instance, the authors do also point out that some of the effects of domperidone may have been due to
changes in either systemic or local CB blood flow.
NA makes up approximately 15–40% of the total catecholamine content of the CB (varying in
different species) and is located in the dense core secretory vesicles in type I cells [80,81]. In acute
hypoxia, NA is secreted from the type I cells into the extracellular space in proportion to the stimulus
intensity [80]. Release of NA from sympathetic terminals and uptake of NA from the circulation
also contributes to the total extracellular NA content in the CB. Despite its concentration being
significantly lower than that of DA, NA still has an important functional role in CB chemoreception.
In a study performed in anaesthetized dogs in the 1970s, it was first observed that infusion of NA
into the carotid artery produced a burst of chemoafferent excitation followed by a more sustained
inhibition [82]. Similar intracarotid infusions of α2-adrenoceptor agonists produced chemoafferent
inhibition and blunted the response to hypoxia in anaesthetized cats [83]. Intracarotid injection of NA
has been shown to inhibit ventilation in goats, a response that was attenuated by both α-adrenoceptor
and D2-receptor antagonists [84]. Sectioning of sympathetic nerves innervating the CB in cats was
shown to have no effect on baseline chemoafferent activity but did augment the frequency during
hypoxia [85]. Direct application of NA to the whole ex vivo CB or dissociated type I cells blunts
neurotransmitter release, Ca2+ currents and the rise in cAMP during hypoxia, effects which are
again dependent on α2-adrenoceptor activation [86,87]. Thus, there is a strong body of evidence to
suggest that endogenous NA released from sympathetic nerves and type I cells promotes inhibitory
feedback via Gαi-coupled α2-adrenoceptors. In contrast, we have seen that venous infusion of NA in
anaesthetized rats elevates ventilation that is partially blocked by section of the CSN [40]. It is possible
that this method of administration produced a more sustained/intense vasoconstriction to arterioles
supplying the CB, leading to a significant reduction in blood flow and local hypoxia. Alternatively,
wide-spread delivery of NA could promote the release of intermediate substances into the systemic
circulation that act indirectly on the CB to evoke chemostimulation. Clearly, there is a need to unify
these contradictory findings. The impact of sympathetic stimulation on CB blood flow requires more
investigation and especially in conditions where there is a known increase in sympathetic tone in
other vascular beds. Furthermore, it is currently unknown what the chronic effect of elevated plasma
NA could be on CB blood flow and function, especially common in conditions such as OSA, SH, HF
and pheochromocytoma.
3. Gαq-Protein-Coupled Receptor Signaling in the Carotid Body
3.1. Angiotensin II
Angiotensin II (Ang II) is a powerful hormone that influences many organs and its level is
increased in important cardiovascular diseases including HF, hypertension and chronic kidney disease.
A wealth of evidence has also shown that Ang II acutely increases CB chemoafferent frequency with
a threshold in the pico/nano-molar range [88,89]. Rises in [Ca2+]i initiated by Ang II can be attenuated
by losartan, an angiotensin 1 (AT1)-receptor antagonist [90]. RT-PCR analysis revealed that both AT1a
and AT1b subtypes are expressed in type I cells and immunohistochemistry has confirmed the presence
of AT1-receptor protein [90,91]. Combined with the finding that an AT2-receptor antagonist was
not able to prevent the Ang II-induced increase in [Ca2+]i, these results suggest that AT1-receptors
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are responsible for modifying CB activity via Ang II. AT1-receptors are coupled to the Gαq protein
and its activation leads to the generation of IP3, via phospholipase C, causing the release of Ca2+ from
intracellular stores [92]. It is now thought that this rise in Ca2+ is sufficient to activate the non-selective
cation channel which contributes to cellular depolarization [93]. Repetitive application of Ang II
can also promote sensory long-term facilitation (sLTF) of chemoafferent nerve activity, an effect
reliant on activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and ROS
generation [89]. AT1-receptor signaling is also key to causing CB sensory long-term facilitation (sLTF)
and persistent sympathoexcitation following acute intermittent hypoxia, in a protein kinase C (PKC),
ROS-dependent manner [94,95]. Whether or not the response to prolonged Ang II desensitizes due to
receptor phosphorylation, β-arrestin recruitment and internalization is yet to be studied in the CB.
Recent reports have indicated that AT1-receptor inhibition does not reduce the HVR or chemoreflex in
healthy humans before or after a short period (8 h) of hypoxia [96]. Furthermore, raising serum Ang II
in healthy individuals does not lead to chemoreflex sensitization [97]. This possibly indicates that Ang
II and AT1-receptor signaling might be more important in pathology or short/long-term CB adaptation
rather than setting chemosensitivity in healthy individuals.
Chronic hypoxia has been shown to increase AT1a and AT1b-receptor mRNA expression in
type I cells as well as CSN sensitivity to Ang II [98]. In situ hybridization, PCR and Western blot
analysis have confirmed the presence of components of the renin-angiotensin system (RAS), including
angiotensinogen and angiotensin-converting enzyme (ACE), in type I cells of the CB, indicative of a local
system [99]. These components are elevated in rat CBs exposed to chronic hypoxia and CIH [99,100].
AT1-receptor protein is also increased in CBs following CIH [101]. It has therefore been suggested
that Ang II may play a role in causing CB hyperactivity in diseases associated with chronic hypoxia
and/or CIH, e.g., in OSA. To support this, heightened sympathetic activity following exposure to CIH
is prevented in rats treated with losartan, an AT1-receptor inhibitor [101]. Translational findings in
humans are currently limited. However, in a recent clinical trial, it was observed that losartan reduced
systolic and diastolic blood pressure in OSA patients without modifying muscle-sympathetic outflow
or ventilation during hypoxia [102]. OSA was fairly well established in these patients and as such, there
may have been irreversible epigenetic remodeling of CB function [103], accounting for the apparent
lack of impact of losartan on CB function. Future studies could evaluate if losartan or similar agents are
more effective in protecting against the development of hypertension in newly diagnosed or more-mild
OSA patients.
In animal models of HF, augmented CB Ang II signaling is also suggested to increase basal
and hypoxic sympathetic outflow and contribute to neurogenic hypertension [104]. AT1-receptor
antagonists reduce chemoafferent firing frequency and renal sympathetic nerve activity in rabbits with
HF but not controls [104]. Furthermore, The AT1-receptor antagonist, L-158,809 (1 µM), significantly
decreases the sensitivity of voltage-dependent K+ current to hypoxia in type I cells isolated from CH
but not control rabbits [105]. These increased actions of Ang II in HF are reported to be mediated by
increased NADPH-oxidase activity and ROS generation [106]. Clinical trials are now called for to
directly assess the role of Ang II and Ang II antagonists in mediating CB hyperactivity and hypertension
in human patients with HF.
3.2. Serotonin (5-HT)
Serotonin (5-HT) is another excitatory neurotransmitter in the CB and the enzymes involved in
its biosynthesis (tryptophan hydroxylase) and transport (5-HT transporters) have been identified in
type I cells, indicating that 5-HT is synthesized locally [107,108]. During normoxia, the release of 5-HT
occurs spontaneously from type I cells in large clusters (ca 20 cells) to establish baseline spike-like
depolarizations [109,110]. Exogenous 5-HT evokes a significant increase in [Ca2+]i in a distinct
population of type I cells [111]. 5-HT binds to the Gαq-linked 5-HT2A-receptor subtype expressed
in type I cells and the stimulatory effect is via a PKC-mediated inhibition of the Ca2+-activated K+
current [110]. Hypoxia induces depolarization of type I cells leading to neurotransmitter release,
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including 5-HT. 5-HT2-receptor antagonists reduce both the number and magnitude of type I cell spike
depolarizations and the hypoxia-stimulated rise in [Ca2+]i [112]. However, nerve-recording studies
have demonstrated that 5-HT does not significantly alter the peak response to hypoxia, but does prolong
the duration of the response [113]. 5-HT has also been implicated in contributing to chemoafferent
hyperactivity in the CB during pathophysiological conditions associated with CIH [114]. 5-HT release
and 5-HT2-receptor activation are crucial for NADPH oxidase (NOX) activation during CIH [114].
Hypoxia induces a significant increase in 5-HT release from type I cells in CIH-treated animals, which
in turn leads to an increase in PKC activity and NADPH-oxidase 2-derived ROS generation, which is
suggested to cause persistent chemoafferent hyperactivity [115]. Taken together, these results suggest
a role for 5-HT in setting CB excitability and in both normal and pathological conditions. However,
as with Ang II, it is not known whether the response to prolonged 5-HT desensitizes and if some of
the longer-lasting effects of 5-HT in pathology are dependent on β-arrestins. In addition, selective
targeting of the CB with 5-HT2-receptor antagonists is yet to be trialed in humans with OSA.
4. Receptors with Dual Gαs/Gαq Signaling
4.1. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and the PAC1-Receptor
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide that was originally
identified in the hypothalamus and was observed to be capable of increasing cAMP content in
pituitary cell cultures [116]. However, since PACAP can be detected in peripheral blood [117], there
is also the potential for systemic actions, including on the CB. PACAP was initially suggested to
exert an excitatory influence on the type I cell by inhibiting background TASK currents and raising
[Ca2+]i [118]. This is now thought to occur via activation of pituitary adenylate cyclase-activating
polypeptide type 1 (PAC1)-receptors. Interestingly, the activation of PAC1-receptors can lead to
stimulation of both Gαs and Gαq signaling pathways. In experiments utilizing the ex vivo intact CB
preparation, it was shown that prolonged PACAP application (50 min, 200 nM) caused a biphasic
response characterized by an initial short-lasting peak 2–3-fold elevation in chemoafferent discharge,
followed by a drop and plateau at approximately 1.5–2-fold above baseline [119]. Whilst inhibitors
of PKA and EPAC did inhibit chemoafferent responses, these were modest compared to the effect of
the PLC inhibitor U73122, which strongly suppressed both the peak and steady-state responses [119].
Thus, although there are roles for both Gαs and Gαq, it is more likely that in this case, Gαq predominates.
Of particular importance is the potential link between PACAP and sudden infant death syndrome
(SIDS) in African Americans [120]. In this pilot study, a significant association was observed between
SIDS and a single nucleotide polymorphism in exon 2 of the PACAP gene, but only in African American
infants and not Caucasians [120]. The reason for the observed differences is still to be elucidated.
Further studies are required to explore this relationship in much larger patient cohorts and in different
ethnicities. However, it is known that neonatal animals that lack the PACAP gene have high mortality
due to significantly reduced respiratory responses to both hypoxia and hypercapnia, and a high
incidence of prolonged apneas [121]. Furthermore, neonatal mice lacking the PAC1-receptor have
a reduced HVR compared to WT littermates [122]. Administration of PACAP-38, an exogenous form
of PACAP, in the rat in situ working heart-brainstem preparation induced a significant increase in
respiratory frequency, an effect that was abolished by CB denervation [123]. PACAP-38 also stabilized
breathing in this preparation, however, this was not modified by CB denervation, indicative of a central,
CB-independent action. Thus, the role for PACAP and the CB in SIDS is still to be defined, and there is
an urgent need to identify more personalized protective therapies for vulnerable infants at particularly
high risk.
4.2. Endothelin
Endothelin (ET) is a 21 amino acid peptide most commonly known for its ability to cause potent
vasoconstriction. The G-protein-coupled receptors ETA and ETB are expressed in the CB type 1 cells
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as well as in the surrounding blood vessels [124]. ETA- and ETB-receptors can be coupled to multiple
G-proteins, including Gαq, Gαs and Gαi,. Given that ET causes type I cell stimulation and an increase
in [Ca2+]i, they are most likely to be linked with Gαq and Gαs in this tissue [125]. The main function of
ET signaling appears to be in mediating CB adaptation to chronic hypoxia and CIH in adults [126,127]
and neonates [128]. In adult rats, chronic hypoxia upregulates ETA- and ETB-receptor expression
in the type I cell and ETA-selective antagonists have a strong impact on chemoafferent discharge,
producing ca 11% inhibition before chronic hypoxia, increasing to ca 50% inhibition after 16 days of
chronic hypoxia [129,130]. In chronic hypoxia, increased endothelin signaling seems to overlap with
enhanced generation of nitric oxide (NO), a substance capable of both increasing and decreasing CB
chemosensitivity dependent on the specific microdomain in which it is produced [129,131]. Further
work is necessary to define the exact role and location of this increased NO generation in chronic
hypoxia. In contrast, exposure to CIH appears to increase expression of ETB but not ETA [124].
Non-selective ET-receptor antagonists have a greater inhibitory effect on chemoafferent activity in CIH
compared to control rat and cat CBs [132,133]. In a recent study, it was suggested that the augmented
ET signaling includes upregulation of PLC and PKC [134]. In neonatal rat CBs, the elevation in
chemoafferent activity is dependent on ETA-receptor stimulation and ROS generation [128]. These
important findings can be advanced further by evaluating ET signaling and CB hyperactivity in
humans and in other CB-mediated pathology, such as HF and spontaneous/essential hypertension.
A summary of G-protein signaling in the CB type I cell is presented in Figure 3.
Figure 3. Summary of G-protein signaling in the carotid body type I cell. The activation of
Gq-protein-coupled receptors (Green) activates phospholipase C (PLC), which in turn leads to
the formation of both inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 will bind to
the endoplasmic reticulum (ER), causing ER Ca2+ efflux. DAG will activate protein kinase C (PKC).
The activation of Gs-protein-coupled receptors (Blue) will activate transmembrane adenylyl cyclase
(tmAC), leading to an increase in intracellular cyclic adenosine monophosphate (cAMP) production,
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which will activate protein kinase A (PKA). The activation of pituitary adenylate cyclase-activating
polypeptide type 1 (PAC1) and endothelin (ET) receptors (Pink) could activate both Gq and Gs
mechanisms. Stimulation of Gi-protein-coupled receptors (Gray) predominantly by dopamine will
inhibit tmAC activity, which in turn decreases cAMP. The overall balance between the concentration
of external ligands and the extent of activation of each of the Gs, Gi and Gq pathways is capable
of acutely fine-tuning the type I cell hypoxic sensitivity. Many of these receptors and signaling
pathways are also involved in physiological and pathological carotid body adaptation. The dashed
circle identifies the position of the CB and type I cells at the carotid bifurcation. Dashed lines denote
receptor activation linking to specific downstream enzymes. Filled lines denote further downstream or
upstream signaling cascades.
5. Other G-Protein Signaling Mechanisms
In addition to being a principal excitatory neurotransmitter, it has been proposed that ATP has
an autocrine and paracrine function in the CB to provide a negative feedback mechanism and amplify
the effects of adenosine, respectively [135,136]. ATP receptors that are also GPCRs include the P2Y1-
and P2Y2-receptor subtypes which are coupled to the Gαq protein and have been identified in the CB.
P2Y2-receptors are localized to the glia-like sustentacular type II cells and administration of ATP
leads to an increase in [Ca2+]i and the opening of pannexin-1 channels, which allow the release of
ATP [135,137]. This ATP-induced ATP release allows for further breakdown of ATP via CD73 to form
adenosine, which can then act on A2A- and A2B-receptors, enhancing adenosine chemoexcitation
in the CB, suggesting cross-communication between type I and type II cells [6]. However, ATP
can also act on P2Y1-receptors located on the type I cell, providing a negative feedback mechanism
at high extracellular concentrations. Studies have shown that high extracellular levels of ATP had
no effect on the resting [Ca2+]i but were able to restrict the increase in [Ca2+]i during hypoxia [136].
Although the exact mechanism is unknown, activation of the P2Y1-receptor has been suggested to
close background ion channels other than the common TASK-like K+ or Na+ channels, resulting in
type I cell hyperpolarization [136].
Similarly, as well as being a key excitatory neurotransmitter, acetylcholine (ACh) also has
a modulatory function acting through Gαq-coupled muscarinic receptors [138,139]. Interestingly,
stimulation of type I cells by methylcholine can be inhibited by histamine, H3-receptor (Gαi) agonists
and SQ22536, suggestive of interaction between Gαi and Gαq pathways [140,141]. The precise
point(s) at which multiple different G-protein pathways converge remains to be revealed. Exploring
the cross-talk between multiple different GPCRs and downstream signaling pathways could be
an interesting area for investigation in CB-mediated cardiovascular disease [78].
6. Conclusions
G-proteins play a crucial role in CB function both in normal physiology and pathology. Activation
of GPCRs in the CB can cause either stimulation or the inhibition of chemoafferent activity dependent
on intricate balance between numerous different neuromodulators, GPCRs and second messenger
systems. Ultimately, changes in the output from the CB mediated by GPCRs will have important
systemic effects, including variations in ventilation, heart rate, blood vessel vasoconstriction and blood
glucose. Importantly, GPCRs have a very significant part in evoking CB hyperactivity, hypertension
and cardiac arrhythmia associated with key conditions such as OSA and HF. Despite this, there is
still no therapy used clinically that directly targets the CB. Thus, translational studies are urgently
required to evaluate if drugs targeting GPCRs can effectively protect against or reverse CB-mediated
cardiovascular disease in humans.
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